Clinical trial
A Phase 1, Open-Label, 4-Part Study to Investigate the Relative Bioavailability and Bioequivalence of Imlunestrant (LY3484356) Test and Reference Formulations and the Effects of Food and Omeprazole on the Pharmacokinetics of Imlunestrant, in Healthy Female Participants of Non-Childbearing Potential
NCT07918859 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open-Label, 4-Part Study to Investigate the Relative Bioavailability and Bioequivalence of Imlunestrant (LY3484356) Test and Reference Formulations and the Effects of Food and Omeprazole on the Pharmacokinetics of Imlunestrant, in Healthy Female Participants of Non-Childbearing Potential
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- August 31, 2027
- Enrollment
- 343 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
healthy
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,100 more trials See the organization page